Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
- DOI
- 10.1007/s40120-023-00460-1
- Published
- 2023 Jun
- Container
- Neurology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40120-023-00460-1,
title = {Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.},
author = {Tahami Monfared AA and Ye W and Sardesai A and Folse H and Chavan A and Kang K and Zhang Q},
year = {2023},
journal = {Neurology and therapy},
doi = {10.1007/s40120-023-00460-1},
url = {https://doi.org/10.1007/s40120-023-00460-1}
}RIS
TY - JOUR TI - Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. AU - Tahami Monfared AA AU - Ye W AU - Sardesai A AU - Folse H AU - Chavan A AU - Kang K AU - Zhang Q PY - 2023 JO - Neurology and therapy DO - 10.1007/s40120-023-00460-1 UR - https://doi.org/10.1007/s40120-023-00460-1 ER -
APA
AA, T. M., W, Y., A, S., H, F., A, C., K, K., & Q, Z. (2023). Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.. Neurology and therapy. https://doi.org/10.1007/s40120-023-00460-1
Source records
- pubmed · retrieved 2026-09-27T10:28:16.477Z